XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock Compensation Plans | 3 Months Ended
--- | ---
Dec. 31, 2017
Share-based Compensation [Abstract] |
Stock Compensation Plans | STOCK COMPENSATION PLANS Under the Company’s 2003 Stock Option Plan, the Company was able to grant options for up to 300,000 shares of common stock to employees, officers, directors and directors emeriti. Under the Company's 2014 Equity Incentive Plan, the Company is able to grant options and awards of restricted stock (with or without performance measures) for up to 352,366 shares of common stock to employees, officers, directors and directors emeriti. Shares issued may be purchased in the open market or may be issued from authorized and unissued shares. The exercise price of each option equals the fair market value of the Company’s common stock on the date of grant. Generally, options and restricted stock vest in 20% annual installments on each of the five anniversaries from the date of the grant, and options generally have a maximum contractual term of 10 years from the date of grant. At December 31, 2017, there were 116,516 shares of common stock available which may be awarded as options or restricted stock pursuant to future grant under the 2014 Equity Incentive Plan. At both December 31, 2017 and 2016, there were no unvested restricted stock awards. There were no restricted stock grants awarded during the three months ended December 31, 2017 and 2016. Stock option activity for the three months ended December 31, 2017 and 2016 is summarized as follows:
| Three Months Ended December 31, 2017 |  | Three Months Ended December 31, 2016
| Number of Shares |  |  | Weighted Average Exercise Price |  |  | Number of Shares |  |  | Weighted Average Exercise Price |
Options outstanding, beginning of period | 380,120 |  |  | $ | 13.23 |  |  | 373,130 |  |  | $ | 9.82 |
Exercised | (6,250 | ) |  | 9.65 |  |  | (12,700 | ) |  | 6.31 |
Forfeited | (4,300 | ) |  | 11.66 |  |  | — |  |  | — |
Options outstanding, end of period | 369,570 |  |  | $ | 13.31 |  |  | 360,430 |  |  | $ | 9.94 |
The aggregate intrinsic value of options exercised during the three months ended December 31, 2017 and 2016 was $124,000 and $157,000, respectively. At December 31, 2017, there were 203,250 unvested options with an aggregate grant date fair value of $499,000, all of which the Company assumes will vest. The aggregate intrinsic value of unvested options at December 31, 2017 was $1.94 million. There were 29,500 options with an aggregate grant date fair value of $75,000 that vested during the three months ended December 31, 2017. At December 31, 2016, there were 221,950 unvested options with an aggregate grant date fair value of $438,000. There were 28,500 options with an aggregate grant date fair value of $67,000 that vested during the three months ended December 31, 2016.
Additional information regarding options outstanding at December 31, 2017 is as follows:
|  | Options Outstanding |  | Options Exercisable
Range of Exercise Prices ($) |  | Number |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (Years) |  | Number |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (Years)
$ 4.01 - 4.55 |  | 10,000 |  |  | $ | 4.28 |  |  | 2.9 |  | 10,000 |  |  | $ | 4.28 |  |  | 2.9
5.86 - 6.00 |  | 39,000 |  |  | 5.94 |  |  | 4.8 |  | 39,000 |  |  | 5.94 |  |  | 4.8
9.00 |  | 78,000 |  |  | 9.00 |  |  | 5.8 |  | 59,800 |  |  | 9.00 |  |  | 5.8
10.26 - 10.71 |  | 131,520 |  |  | 10.57 |  |  | 7.3 |  | 48,070 |  |  | 10.56 |  |  | 7.2
15.67 |  | 53,050 |  |  | 15.67 |  |  | 8.8 |  | 9,450 |  |  | 15.67 |  |  | 8.8
29.69 |  | 58,000 |  |  | 29.69 |  |  | 9.8 |  | — |  |  | N/A |  |  | N/A
|  | 369,570 |  |  | $ | 13.31 |  |  | 7.2 |  | 166,320 |  |  | $ | 8.83 |  |  | 6.0
The aggregate intrinsic value of options outstanding at December 31, 2017 and 2016 was $4.89 million and $3.86 million, respectively. As of December 31, 2017, unrecognized compensation cost related to non-vested stock options was $446,000, which is expected to be recognized over a weighted average life of 2.25 years.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration